Data as of Dec 10
| -0.23 / -3.68%|
The 4 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 14.50, with a high estimate of 17.00 and a low estimate of 12.00. The median estimate represents a +140.86% increase from the last price of 6.02.
The current consensus among 5 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.